print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
21/10/2012 (Added to site)
Author(s): Tamzali, Y.; Borde, L.; Rols, M. P.; Golzio, M.; Lyazrhi, F.; Teissie, J.

Successful treatment of equine sarcoids with cisplatin electrochemotherapy: A retrospective study of 48 cases

Journal: Equine Veterinary Journal, 44 (2012), pp. 214-220
DOI: 10.1111/j.2042-3306.2011.00425.x
Request reprint  |  Tell your friend  | 

Abstract:

Reasons for performing study: Sarcoids are the commonest form of equine skin tumour. Several therapeutic measures have been described but none is considered to be universally effective. Electrochemotherapy (ECT) is a new anticancer therapy that utilises electrical field pulses to induce increased cell membrane permeability to antitumour hydrophilic drugs, such as cisplatin. The increased intracellular concentration of the drugs has a significant therapeutic benefit. The procedure has not been previously reported in a large number of horses.

Objective: To validate ECT as a novel alternative treatment for equine sarcoids.

Methods: Aretrospective study evaluating the efficacy of cisplatin ECT in the treatment of equine sarcoidswas performed. Electrochemotherapy treatments were applied under general anaesthesia at 2 week intervals with or without prior excision or debulking. Electric pulses were directly applied to the lesions following intra-tumoural injections of an aqueous solution of cisplatin.

Results: One-hundred-and-ninety-four sarcoids on 34 horses, 2 ponies, 11 donkeys and one mulewere treated with ECT. The 4 year nonrecurrence ratewas 97.9% for animals (47/48) and 99.5% (193/194) for tumours. When ECT was used as a single treatment, a significant influence of tumour size (r = 0.55) on the number of treatments required for cure was shown. When prior surgery was performed, there was a significant influence (P<0.001) of the excision quality (complete or incomplete) and the healing mode (closed or open wound) on the number of treatments. The most common adverse effect was a slight oedematous reaction for lesions located on thin skin regions.

Conclusion and clinical relevance: Results demonstrate that ECT, with or without concurrent tumour debulking, is an effective alternative for treatment of equine sarcoids.


Keywords: chemotherapy    cisplatin    electrochemotherapy    horse    sarcoids   

Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: